First published 9/28/2026, 9:46:15 AM · Last updated 9/28/2026, 9:46:15 AM

Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup

Journal article reporting a MARIPOSA-2 analysis comparing amivantamab plus chemotherapy versus chemotherapy in EGFR‑mutant advanced non‑small cell lung cancer after progression on osimertinib, focused on the Asian subgroup. The supplied source text gives no information on results, outcomes, or sample size.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 6/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The analysis addresses treatment comparisons for Asian patients with EGFR‑mutant advanced non‑small cell lung cancer after osimertinib progression.

Sources

Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup

Report an issue